21 results about "Helicobacter Infections" patented technology

The invention discloses lactobacillus fermented concentrated asparagus extracted juice with the effect of preventing helicobacter pylori infection as well as preparation and application of the lactobacillus fermented concentrated asparagus extracted juice, and belongs to the technical field of food biotechnology and microbial fermentation. The concentrated asparagus beverage is prepared from the following raw materials: 20-50 parts of concentrated asparagus extract juice, 50-80 parts of purified water, 2-6 parts of glucose, 2-4 parts of white granulated sugar, 0.01-0.1 part of sodium D-isoascorbate and 0.001-0.01 part of compound lactic acid bacteria. The fermented and concentrated asparagus extraction juice is prepared by taking asparagus as a raw material, crushing, extracting, concentrating and fermenting, and the antioxidant capacity, the inhibition capacity on helicobacter pylori, the prevention and treatment effects on helicobacter pylori infection and the like of the obtained fermented and concentrated asparagus extraction juice are obviously improved. The asparagus extracted juice can be widely applied to the field of prevention and / or treatment of helicobacter pylori infection, and is particularly applied to preparation of drugs for prevention and / or treatment of helicobacter pylori infection.

The invention relates to the use of herbal preparation, characterized by presence of 4 dominant compounds (carvacrol a from about 35% to about 50%, γ-terpinene from about 10% to about 30%, thymol from about 10% to about 25%, p-cymene from about 8% to about 20%, as expressed in % of total peak area in GC / MS chromatogram), obtained by mixing at least two essential oils from species selected from the group of genera Satureja L., Origanum L. and Thymus L., to prepare food supplement or medicament for treatment and prevention of gastric Helicobacter pylori infection in humans. The mixture may be placed on liquid or solid carrier and capsulated in non gastro-resistant capsules. The invention also relates to dosage regiment of herbal preparation for treatment and prevention of patients with Helicobacter pylori infection which leads to successful eradication of bacteria without any side-effects.

This invention relates to the field of pharmaceutical formulation technology, specifically to a sustained-release formulation of rifabutin, and more specifically, to a sustained-release rifabutin formulation composition for treating Helicobacter pylori infection. The key technical point of this invention is that it uses a novel antibiotic for treating Helicobacter pylori infection as the active ingredient, supplemented with specific inactive ingredients, including a hydrophilic gel-type matrix sustained-release material, a swelling agent, a buoyancy aid, and a lubricant. Through the synergistic effect of the hydrophilic gel-type matrix sustained-release material, the swelling agent, and the buoyancy aid, the composition can rapidly swell in gastric juice and maintain a floating state, thereby significantly prolonging the residence time of the formulation in the stomach and upper small intestine. This invention solves the technical problem of conventional formulations having a short residence time in the stomach and requiring frequent administration to maintain an effective antibacterial concentration, achieving the goal of effectively eradicating Helicobacter pylori by reducing the number of doses while maintaining an effective concentration at the site of infection for a longer period.

This invention provides the application of *Bifidobacterium breve* in the preparation of products for treating gastric ulcers and gastric inflammation caused by *Helicobacter pylori*, belonging to the field of microbial technology. The *Bifidobacterium breve* NKU BB1-2 of this invention, with accession number GDMCC NO: 65956, can antagonize *Helicobacter pylori* colonization and alleviate the aggravation of gastric ulcers caused by *Helicobacter pylori*. In vitro, *Bifidobacterium breve* NKU BB1-2 exhibits good antagonistic ability against *Helicobacter pylori*, significantly inhibiting its colonization and growth. Animal experiments show that *Bifidobacterium breve* NKU BB1-2 can alleviate the aggravation of gastric ulcers caused by *Helicobacter pylori* infection in vivo, manifested as reduced gastric mucosal damage, reduced gastric inflammation, and increased gastric pH. Furthermore, *Bifidobacterium breve* NKU BB1-2 can significantly enhance gastric microbial diversity, regulate and improve the gastric microbial structure, and assist in antagonizing and eradicating *Helicobacter pylori* infection.

This invention provides a composition, preparation method, and application for preventing Helicobacter pylori infection. The composition comprises a mixture of outer membrane vesicles and a solution of *Ackermania pseudomallei* bacteria; the outer membrane vesicle mixture is composed of outer membrane vesicles of *Salmonella* mutant strain QS0074 and outer membrane vesicles of *Escherichia coli* Nissle 1917 at a weight ratio of 2:1; the weight-to-volume ratio of the outer membrane vesicle mixture to the *Ackermania pseudomallei* bacterial solution is 1 mg:1 mL. The composition obtained by this invention significantly outperformed the control group in challenge tests, demonstrating a highly effective preventive effect against Helicobacter pylori infection. Furthermore, the components of the composition of this invention exhibit significant synergistic effects in inducing secretory IgA levels in mice and inducing resistance to Helicobacter pylori infection, showing promising application prospects.

In particular, the present invention relates to a composition consisting of 2 '-fucosyllactose and 3-fucosyllactose. The composition of the present invention is based on fucosyllactose, is used for preventing and / or treating helicobacter pylori infection, and is a safe, effective and less susceptible to drug resistance.

Recombinant blood group antigen-binding adhesin (BabA) can be used in a composition to raise humoral immune response i.e. antibodies, that target conserved structural epitopes in the fucosylated blood group antigen Lewis b (Leb) antigen binding domain in the blood group antigen-binding adhesin (BabA). Such broadly Leb-blocking antibodies can reduce the gastric mucosal attachment of Helicobacter pylori (H. pylori) to human gastric mucosa. This approach can be used for preventing and / or alleviating gastric disease in a subject diagnosed with H. pylori infection, said gastric disease chosen from gastroesophageal reflux disease, chronic active gastritis, peptic ulcer diseases, gastric ulcer disease, gastric cancer gastritis and gastric cancer, in particular gastric cancer. It also becomes possible to identify subjects that carry BabA positive H. pylori infections and subjects that are at risk of developing severe gastric disease, such as peptic ulcer diseases, gastric ulcer disease, gastritis with metaplasia and gastric cancer.

The present application relates to the field of microorganisms, and discloses a lactobacillus plantarum with antibacterial efficacy and application thereof, wherein the lactobacillus plantarum has a preservation number of CGMCC No.33151.The strain provided by the present application has strong abilities of resisting bile salt, resisting gastric acid, producing acid and producing H2O2, and has strong bacteriostatic effects on common pathogenic bacteria such as staphylococcus aureus, candida albicans, escherichia coli, salmonella and helicobacter pylori, and can inhibit the activity of urease, interfere with the colonization of helicobacter pylori and the like, so as to inhibit helicobacter pylori infection, reduce the symptoms of helicobacter pylori infection and reduce the disease degree of colonitis mice, and can be used for preparing a microbial preparation and has potential for preparing a medicine for preventing and / or treating diseases caused by helicobacter pylori infection.

New probiotic clones have emerged that have enhanced activity against Helicobacter pylori infection. The new clones are derived from selected strains of Lactobacillus acidophilus and Bifidobacterium animalis lactis sp. They are advantageously insensitive to antibiotics currently used to treat Helicobacter pylori infection, which makes them ideal for co-therapy with said antibiotics in the eradication of Helicobacter pylori infection. Synergistic effects of combinations between the present probiotics and their strong adjuvant effect on the action of antibiotics on Helicobacter pylori are reported herein.

The application discloses application of Wangshi Baochi pills in treatment of Helicobacter pylori infection and belongs to the technical field of medicines. The application provides the application of the Wangshi Baochi pills in treatment of Helicobacter pylori infection, which can achieve ideal treatment effects under the condition that the dosage of antibiotics is halved and bismuth agents are not used, and can better relieve the clinical symptoms of pain, belching, acid regurgitation and heartburn.

Described are analogs of aztreonam and disulfiram of Formula I, II, and III. These compounds can be used to treat bacterial infections in a subject. Also disclosed is the use of aztreonam and disulfiram for treating H. pylori infections. Combinations of the disclosed analogs and / or aztreonam and disulfiram with additional antibiotics and proton pump inhibitors are also disclosed.

The invention discloses a gastric-soluble sustained-release tablet for preventing and treating helicobacter pylori infection and a preparation method of the gastric-soluble sustained-release tablet. The gastric-soluble sustained-release tablet comprises an active component and a sustained-release auxiliary material, the active component comprises a CagA protein targeting polypeptide, the CagA protein targeting polypeptide is a target HpCagA protein C terminal, and the amino acid sequence is shown as SEQ ID NO: 1. According to the sustained-release tablet, cell penetrating polypeptide targeting CagA protein is taken as an active ingredient, the effect is achieved by blocking CagA phosphorylation and downstream signal channels, meanwhile, the gastric-soluble sustained-release dosage form design is combined, the local high-concentration and long-acting effect is achieved, the dual effects of toxicity reduction and bacterium control are achieved, and the problems of drug resistance and side effects of antibiotics are solved.

Described herein is a method of diagnosing a H. pylori infection in a subject. The method comprises: determining a fatty acid profile in a stool sample of the subject; and comparing the fatty acid profile with a reference profile indicating H. pylori infection or a second reference profile indicating H. pylori infection. The subject is diagnosed to have H. pylori infection when a level of at least one fatty acid in the fatty acid profile is different than a level of the at least one fatty acid in the first reference profile; or a level of at least one fatty acid in the fatty acid profile matches a level of the at least one fatty acid in the second reference profile. Also described is a method of treating H. pylori infection based on the diagnostic method.

The invention discloses an application of high-oxygen water and Wuji decoction in a medicine for treating helicobacter pylori infectious gastrointestinal diseases, and relates to the technical field of biological medicine, research finds that the high-oxygen water and Wuji decoction have a remarkable effect in treating the helicobacter pylori infectious gastrointestinal diseases, and particularly, the high-oxygen Wuji decoction has a remarkable effect in treating the helicobacter pylori infectious gastrointestinal diseases by inhibiting an S100A8 / S100A9-TLR4-p38 signal channel. The expression of S100A8, S100A9, TLR4 and p38 is down-regulated, the generation of inflammatory factors IL-8 and TNF-alpha is inhibited, and the inflammatory response of gastric mucosa is relieved; meanwhile, by regulating and controlling an HSP70 / NF-kappa B signal channel, the expression of HSP70 is up-regulated, the expression of NF-kappa B is reduced, and the inflammatory response of gastric mucosa is relieved; finally, the high-oxygen Wuji decoction improves the expression level of SIgA and protects intestinal barriers; the ratio of the phylum firmicalis to the phylum bacteroides is recovered, the richness of intestinal flora species is improved, and the structure of the intestinal flora is adjusted.

The application belongs to the technical field of microorganisms, and discloses a kind of fermented lactobacillus mucus TY-H27 and its lysate in the application of inhibiting inflammation caused by helicobacter pylori infection, and the preservation number of the fermented lactobacillus mucus TY-H27 is CGMCC No.37936.The lysate of the fermented lactobacillus mucus TY-H27 of the application can effectively inhibit the inflammatory response caused by helicobacter pylori infection.

This invention relates to the field of biotechnology, specifically to a gastric-targeted glycyrrhetinic acid self-assembled nanodelivery system, its preparation method, and its application in inhibiting Helicobacter pylori infection. The nanoassembly is formed by the self-assembly of a system comprising glycyrrhetinic acid and metal ions; wherein the metal ions and glycyrrhetinic acid self-assemble through non-covalent interactions to form a structure with a nanoscale morphology; the nanoscale morphology is selected from at least one of nanotubes, nanoribbons, and nanovesicles. The nanoassembly of this invention, constructed by the self-assembly of glycyrrhetinic acid driven by metal ions, can achieve long-term retention in the stomach (>24 h) and effectively penetrate the gastric mucus layer, thereby maintaining a high effective concentration at the site of gastric inflammation. Furthermore, when applied to the treatment of inflammatory diseases of the gastrointestinal tract, it can effectively inhibit and kill pathogenic bacteria without easily inducing bacterial resistance, maintaining the diversity of the gastrointestinal flora, and thus avoiding the dysbiosis caused by traditional antibiotic treatment, showing broad application prospects.

The invention discloses lactobacillus rhamnosus with an effect of preventing helicobacter pylori infection and application of the lactobacillus rhamnosus, and belongs to the technical field of biological medicines and microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 21, 2025, the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO. 34273. The JGSLR02 is a lactobacillus rhamnosus strain with excellent probiotic characteristics, and especially has excellent helicobacter pylori antagonism potential in vitro. A helicobacter pylori infected C57BL / 6 mouse model proves that the rhamnosus lactobacillus has the capability of preventing occurrence and development of mouse helicobacter pylori infection, and can antagonize helicobacter pylori in vivo, prevent helicobacter pylori infection, relieve inflammatory response and promote gastric mucosa repair.

The invention discloses a lactobacillus rhamnosus HL-JO04 capable of inhibiting helicobacter pylori and improving GABA (gamma-aminobutyric acid) concentration of a nervous system and application of the lactobacillus rhamnosus HL-JO04. The lactobacillus rhamnosus HL-JO04 not only can effectively inhibit growth of the helicobacter pylori, but also can prevent the helicobacter pylori from being adhered to epithelial cells of human gastric mucosa, and has the characteristic of improving GABA concentration of a hippocampus. The strain is high in growth and reproduction rate, high in freeze-dried bacterial powder activity and high in digestive tract tolerance, and is suitable for industrial application. The high-activity lactobacillus rhamnosus capable of inhibiting the growth and colonization of the helicobacter pylori and producing the GABA at high yield is adopted, so that a wider treatment choice is provided for treating helicobacter pylori infection as well as flora imbalance and related mental problems caused by the use of a large dose of antibiotics.

The invention discloses an oral medicine containing sodium dehydroacetate, which is used for treating helicobacter pylori infection. In order to solve the problems of antibiotic resistance and gastrointestinal tract microecological disorder caused by the existing quadruple therapy, free molecules of the medicine disclosed by the invention under the gastric acid condition have strong lipophilicity, can efficiently penetrate through a gastric mucous layer and bacterial cell membranes, and can cause bacterial energy depletion death by blocking tricarboxylic acid cycle and energy metabolic centers such as succinate dehydrogenase. Animal experiments prove that the curative effect of reducing Hp colonization is equivalent to or even better than that of quadruple therapy. As a non-antibiotic bacteriostatic agent, the product has the advantages that drug resistance is not easy to generate due to multi-target action, normal intestinal flora is not damaged, flora imbalance and secondary infection are effectively avoided, and the safety is obviously improved.

The present application belongs to the field of medical data mining, and particularly relates to a kind of helicobacter pylori stomach video full-automatic intelligent analysis system and marking method thereof, including image acquisition module, image preprocessing module, effective frame module, anatomical position positioning module, deep learning module and marking display module, the image acquisition module is used to obtain video stream, the image preprocessing module is used to pre-process the image of video stream, the effective frame module is used to classify and screen the image of video stream, the anatomical position positioning module is used to identify the specific position of endoscope currently located in stomach, the deep learning module is used to predict the helicobacter pylori infection probability of different anatomical position pictures.The present application does not need doctor to step on pedal to input specific picture to identify helicobacter pylori infection in test process, the whole process does not need manual intervention, and full automation and high intelligence can be achieved.

A method of treating patients who are positive for Helicobacter pylori infection comprises determining that a first patient who is positive for Helicobacter pylori infection has a body mass index corresponding to normal weight or overweight; determining that a second patient who is positive for Helicobacter pylori infection has a body mass index corresponding to obese or extremely obese; and administering to both the first patient and the second patient, for 14 days, a rifabutin-based triple therapy consisting essentially of rifabutin, amoxicillin and omeprazole or an equivalent amount of a pharmaceutically acceptable salt thereof, wherein, after treatment is complete, there is no substantial difference in the efficacy of the treatment when the treatment is administered to the first patient or the second patient.